Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Tikomed.

    Client Virtual Booth

    TIKOMED

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Tikomed
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    P.O. Box 81 263 03 Viken SWEDEN
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tikomed.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tikomed's Drug Candidate ILB® Inhibited Infection of Human Cells by Dengue, Zika and Yellow Fever Viruses in Vitro, Providing Further Support for Its B...

    Details:

    ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles.


    Lead Product(s): LMW-dextran Sulfate

    Therapeutic Area: Infections and Infectious Diseases Product Name: ILB

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tikomed's Ilb® Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanisms Able to Target All Neuroinflammation-dri...

    Details:

    These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects.


    Lead Product(s): ILB

    Therapeutic Area: Neurology Product Name: ILB

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 31, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candidate ILB

    Details:

    The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.


    Lead Product(s): ILB

    Therapeutic Area: Neurology Product Name: ILB

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: IQVIA

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tikomed's ILB® Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat

    Details:

    The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.


    Lead Product(s): Dextrans

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ILB

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search